68302-57-8 | 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid

Packsize	Purity	Availability	Price	Discounted Price
50mg	98%	in stock	$18.00	$12.00
100mg	98%	in stock	$22.00	$15.00
250mg	98%	in stock	$28.00	$19.00
1g	98%	in stock	$58.00	$40.00
5g	98%	in stock	$139.00	$97.00
25g	98%	in stock	$387.00	$271.00
50g	98%	in stock	$579.00	$406.00
100g	98%	in stock	$1,070.00	$749.00

Description

• Catalog Number: AB43799
• Chemical Name: 2-amino-5-oxo-7-(propan-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid
• CAS Number: 68302-57-8
• Molecular Formula: C16H14N2O4
• Molecular Weight: 298.2934
• MDL Number: MFCD00864790
• SMILES: CC(c1ccc2c(c1)c(=O)c1c(o2)nc(c(c1)C(=O)O)N)C

Computed Properties

• Complexity: 467
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 22
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 2
• XLogP3: 3.1

Literature

• An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.

  Nature medicine 20130301

• Neuron-specific non-classical release of prothymosin alpha: a novel neuroprotective damage-associated molecular patterns.

  Journal of neurochemistry 20121001

• Amlexanox is as effective as dexamethasone in topical treatment of erosive oral lichen planus: a short-term pilot study.

  Oral surgery, oral medicine, oral pathology and oral radiology 20120501

• Development of a measure to assess effective listening and interactive communication skills in the delivery of children's rehabilitation services.

  Disability and rehabilitation 20120101

• New Evidence-Based Treatment Approach in Behçet's Disease.

  Pathology research international 20120101

• Clinical inquiry. What is the most effective way to treat recurrent canker sores?

  The Journal of family practice 20111001

• Topical immunomodulators for management of oral mucosal conditions, a systematic review; Part II: miscellaneous agents.

  Expert opinion on emerging drugs 20110301

• Nicolaus Copernicus: not only a great astronomer but also a physician.

  Journal of nephrology 20110101

• Variable initial swing side and prolonged double limb support represent abnormalities of the first three steps of gait initiation in patients with Parkinson's disease with freezing of gait.

  Frontiers in neurology 20110101

• Molecular level interactions of S100A13 with amlexanox: inhibitor for formation of the multiprotein complex in the nonclassical pathway of acidic fibroblast growth factor.

  Biochemistry 20100323

• Cromoglycate drugs suppress eicosanoid generation in U937 cells by promoting the release of Anx-A1.

  Biochemical pharmacology 20090615

• RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.

  Journal of translational medicine 20090101

• A clinical evaluation of amlexanox oral adhesive pellicles in the treatment of recurrent aphthous stomatitis and comparison with amlexanox oral tablets: a randomized, placebo controlled, blinded, multicenter clinical trial.

  Trials 20090101

• PDE4 inhibitors: current status.

  British journal of pharmacology 20081001

• [Local Treatment of stomatitis aphthosa].

  Medizinische Monatsschrift fur Pharmazeuten 20080901

• Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops.

  Clinical ophthalmology (Auckland, N.Z.) 20080901

• Synergistic Ca2+ and Cu2+ requirements of the FGF1-S100A13 interaction measured by quartz crystal microbalance: an initial step in amlexanox-reversible non-classical release of FGF1.

  Neurochemistry international 20080501

• Review of over-the-counter treatments for aphthous ulceration and results from use of a dissolving oral patch containing glycyrrhiza complex herbal extract.

  The journal of contemporary dental practice 20080301

• Effectiveness of two oral pastes for the treatment of recurrent aphthous stomatitis.

  Oral diseases 20070901

• Mucocutaneous lesions of Behcet's disease.

  Yonsei medical journal 20070831

• An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial.

  Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20061001

• Evidence for serum-deprivation-induced co-release of FGF-1 and S100A13 from astrocytes.

  Neurochemistry international 20060801

• A late cutaneous response in actively sensitized rats: a new method for evaluating the efficacy of antiallergic drugs.

  Journal of pharmacological sciences 20060801

• Voltage-dependent N-type Ca2+ channel activity regulates the interaction between FGF-1 and S100A13 for stress-induced non-vesicular release.

  Cellular and molecular neurobiology 20060501

• The efficacy of amlexanox OraDisc on the prevention of recurrent minor aphthous ulceration.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20060201

• Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein.

  Mediators of inflammation 20060101

• Molecular mechanism of inhibition of nonclassical FGF-1 export.

  Biochemistry 20051129

• A comparative study of the efficacy of Aphtheal in the management of recurrent minor aphthous ulceration.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20050801

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• Amlexanox for the treatment of recurrent aphthous ulcers.

  Clinical drug investigation 20050101

• Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox.

  The Biochemical journal 20030901

• Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein.

  Biochemical and biophysical research communications 20020412

• Selecting topical and systemic agents for recurrent aphthous stomatitis.

  Cutis 20010901

• The precursor but not the mature form of IL1alpha blocks the release of FGF1 in response to heat shock.

  The Journal of biological chemistry 20010216

• Treatment strategies for recurrent oral aphthous ulcers.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010101

• The comparative release of FGF1 by hypoxia and temperature stress.

  Growth factors (Chur, Switzerland) 20010101

• Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase.

  International archives of allergy and applied immunology 19870101